- Arvinas (ARVN, Financial) to present preclinical data on ARV-393 at AACR 2025.
- The data focuses on ARV-393's combination potential with standard lymphoma treatments.
- ARV-393 targets the B-cell lymphoma 6 protein, a major driver of B-cell lymphomas.
Arvinas, Inc. (ARVN), a clinical-stage biotechnology company, has announced that it will present new preclinical combination data for its investigational PROTAC BCL6 degrader, ARV-393, at the American Association for Cancer Research® (AACR) Annual Meeting from April 25-30, 2025, in Chicago, Illinois. The poster presentation is scheduled for April 28, 2025, from 9:00 a.m. to 12:00 p.m. CT.
ARV-393 is designed to target and degrade the B-cell lymphoma 6 protein (BCL6), which is a transcriptional repressor and a key driver of B-cell lymphomas. The presentation will highlight ARV-393's potential to be combined with biologics or small-molecule inhibitors, demonstrating significant tumor regression in diffuse large B-cell lymphoma models.
The ongoing research explores the effectiveness of ARV-393 in combination with various standard of care therapies for lymphoma, aiming to address the traditional undruggable nature of BCL6 and improve treatment outcomes for patients with relapsed/refractory non-Hodgkin lymphoma. Arvinas, headquartered in New Haven, Connecticut, continues to develop a new class of drugs based on its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform.
